CytoMed Therapeutics (GDTC) Total Non-Current Liabilities (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $325696.2 as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 3.81% to $325696.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $325696.2 through Dec 2025, up 3.81% year-over-year, with the annual reading at $328266.0 for FY2025, 7.46% up from the prior year.
  • Total Non-Current Liabilities hit $325696.2 in Q4 2025 for CytoMed Therapeutics, up from $313744.9 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $408558.5 in Q4 2021 to a low of $302033.6 in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $338537.3 across 5 years, with a median of $325696.2 in 2025.
  • Biggest five-year swings in Total Non-Current Liabilities: fell 16.13% in 2022 and later rose 3.88% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $408558.5 in 2021, then dropped by 16.13% to $342653.2 in 2022, then dropped by 11.85% to $302033.6 in 2023, then rose by 3.88% to $313744.9 in 2024, then increased by 3.81% to $325696.2 in 2025.
  • Business Quant data shows Total Non-Current Liabilities for GDTC at $325696.2 in Q4 2025, $313744.9 in Q4 2024, and $302033.6 in Q4 2023.